Andrea van Elsas
Partner at Third Rock Ventures
Oakland, California
Writes $100K – $5M checks · typically $100K
About
Andrea van Elsas joined Third Rock Ventures as a venture partner in 2020 and became partner in 2022. He was previously CSO at Aduro Biotech, co-founded BioNovion, held immuno-oncology roles at Organon, and is a co-inventor on the original anti-CTLA-4 patents behind ipilimumab.
Invests in
BiotechHealthtechMedical Devices
Investments
Board seats
Azalea TherapeuticsClasp TherapeuticsLava Therapeutics
Per the firm's website.
Colleagues at Third Rock Ventures
Abbie Celniker
Investor at Third Rock Ventures
Adam Tebbe
Investor at Third Rock Ventures
Alan Ezekowitz
Investor at Third Rock Ventures
Alison Connors
Investor at Third Rock Ventures
Amanda Chan
Investor at Third Rock Ventures
Andrew Warren
Senior Associate at Third Rock Ventures
Angelo Severino
Investor at Third Rock Ventures
Ava Brunelle
Investor at Third Rock Ventures
Network12
Abbie Celniker
Investor at Third Rock Ventures
Alan Ezekowitz
Investor at Third Rock Ventures
Andrew Warren
Senior Associate at Third Rock Ventures
Barbara Weber
Venture Partner at Third Rock Ventures
Beryl Cummings
Senior Associate at Third Rock Ventures
Cary Pfeffer
Investor at Third Rock Ventures
Charles Homcy
Investor at Third Rock Ventures
Christoph Lengauer
Partner at Third Rock Ventures
Craig Muir
Investor at Third Rock Ventures
David Kaufman
Investor at Third Rock Ventures
George C. Petrocheilos
Managing Partner at Catalio Capital Management
George Xu
Senior Associate at Third Rock Ventures
Investors connected to Andrea in public investor directories — a warm-intro map.